Genoplan is a leading company in Korea's genetic analysis market as well as in the Asian genomic information analysis market, including Japan. The company offers a genetic diagnostic kit that analyzes genes from a single saliva sample to reveal a wide range of health data, and provides services to a diverse range of domestic and international clients — including insurance sales companies seeking to design personalized products, pharmaceutical companies aiming to reduce new drug development costs and improve efficacy using genetic data, and cosmetics firms. Genoplan has also achieved commercialization in Asian markets including Japan and Indonesia.

As data — alongside artificial intelligence — has emerged as the most critical factor in population genomics, Genoplan aims to integrate genomic data from Far East Asia including Korea, as well as Southeast Asian countries such as Indonesia and Thailand, to address the inequality in genomic data currently skewed toward Europeans and open a future where anyone can access and utilize their own genetic information.

Recognized for the excellence of its deep learning-based polygenic risk score technology for disease prediction and its NGS-based expanded carrier screening technology, Genoplan was selected for the '2022 Korea AI Startup 100 Project.' Genoplan has recently developed an AI model integrated with NGS technology to build a prediction model covering rare genetic variants, for which it has filed a patent. Going forward, the company plans to advance genomics beyond disease diagnosis to enable prediction of future disease risk even in healthy individuals.